J&J nabs FDA nod for Ponvory, joining Novartis, Bristol Myers in crowded MS market

Another oral multiple sclerosis drug is here, challenging a slate of existing players that includes heavyweights Novartis, Bristol Myers Squibb, Sanofi and Biogen.

Johnson & Johnson’s newly FDA-approved Ponvory, also known as ponesimod, is yet another S1P modulator to enter the U.S., joining Novartis’ aging blockbuster Gilenya and its follow-on Mayzent, as well as Bristol Myers’ newly approved Zeposia.